Critical biomarkers guiding pan-cancer targeted therapy have emerged, emphasizing the importance of detecting multiple gene mutations in cancer patients for precise and effective treatment. The AmoyDx HANDLE Classic Panel encompasses 40 key solid tumor genes, enabling the detection of common mutations to support clinical therapeutic decisions with rapid turnaround time (TAT).
Mutations( Hover over each mutational type to highlight genes covered )
All
AKT1
AKT1
SNV/INDELS
ALK
ALK
FUSIONS
SNV/INDELS
BRAF
BRAF
SNV/INDELS
CTNNB1
CTNNB1
SNV/INDELS
DDR2
DDR2
SNV/INDELS
EGFR
EGFR
SNV/INDELS
ERBB2
ERBB2
CNV
SNV/INDELS
ESR1
ESR1
SNV/INDELS
FGFR1
FGFR1
FUSIONS
SNV/INDELS
FGFR2
FGFR2
FUSIONS
SNV/INDELS
FGFR3
FGFR3
FUSIONS
SNV/INDELS
FGFR4
FGFR4
SNV/INDELS
HRAS
HRAS
SNV/INDELS
IDH1
IDH1
SNV/INDELS
IDH2
IDH2
SNV/INDELS
KEAP1
KEAP1
SNV/INDELS
KIT
KIT
SNV/INDELS
KRAS
KRAS
SNV/INDELS
MAP2K1
MAP2K1
SNV/INDELS
MET
MET
CNV
FUSIONS
SNV/INDELS
NFE2L2
NFE2L2
SNV/INDELS
NRAS
NRAS
SNV/INDELS
NTRK1
NTRK1
FUSIONS
SNV/INDELS
NTRK2
NTRK2
FUSIONS
SNV/INDELS
NTRK3
NTRK3
FUSIONS
SNV/INDELS
PDGFRA
PDGFRA
SNV/INDELS
PIK3CA
PIK3CA
SNV/INDELS
POLE
POLE
SNV/INDELS
PTEN
PTEN
SNV/INDELS
RB1
RB1
SNV/INDELS
RET
RET
FUSIONS
SNV/INDELS
ROS1
ROS1
FUSIONS
SNV/INDELS
STK11
STK11
SNV/INDELS
TP53
TP53
SNV/INDELS
CDK4
CDK4
CNV
DPYD
DPYD
SNP
MYC
MYC
CNV
NKX2-1
NKX2-1
CNV
NRG1
NRG1
FUSIONS
UGT1A1
UGT1A1
SNP
Specifications
Sample type
FFPE
Alterations detected
SNV, InDel, Fusion, CNV, MSI
DNA input
minimum 50 ng DNA and 30 ng RNA
Publications
1. Minghao Wang, Hongtao Xu, Qiang Han & Liang Wang (2023) Significance of YAP1–MAML2 rearrangement and GTF2I mutation in the diagnosis and differential diagnosis of metaplastic thymoma, Annals of Medicine, 55:2.
2. Lu, S., Pan, H., Wu, L. et al. Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial. Sig Transduct Target Ther 8, 249 (2023).
Inquiry